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Cost and logistics of alternative roll-out options for implementing
human papillomavirus testing as a triage in cervical screening:
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BACKGROUND: Previous studies have indicated that human papillomavirus (HPV) testing as a triage for managing equivocal cytology is
cost-effective. The aim of this study was to assess the costs of alternative roll-out options.
METHODS: Detailed cost estimates were collected from six laboratories where HPV triage had been implemented. Costs were
assessed for the two different service delivery models that were implemented; a ‘hub and spoke model’ of central HPV testing in a
microbiology laboratory with separate cytology laboratories, and an ‘integrated model’ where HPV testing was conducted within the
cytology laboratory.
RESULTS: Comparison of alternative delivery models indicated that setting up HPV processing within existing cytology laboratory, i.e.,
an ‘integrated cytology/HPV laboratory’ generated savings in staff time amounting to between d2.54 and 4.86 per sample processed.
Running full HPV testing batches was also an important consideration. For full batches to be run on a twice weekly basis requires
having no more than two laboratories per Strategic Health Authority.
CONCLUSIONS: To be cost-efficient, and to meet turn-around times, HPV testing needs to be conducted at integrated cytology/HPV
testing centres with sufficient throughput to run full batches of HPV tests.
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A number of economic analyses have been conducted that suggest
that compared with repeat cytology it would be more cost-effective
to manage women with low-grade cervical cytology results by
utilising human papillomavirus (HPV) testing as a triage to refer
women at higher risk for immediate colposcopy and returning
HPV negative women to routine screening (Kim et al, 2002;
Sherlaw-Johnson, Philipps, 2004; Legood et al, 2006). The
implementation of HPV triage can be delivered in a number of
different ways with HPV testing and cytology being performed in
the same centre or samples sent to a central HPV testing centre
based in a microbiology laboratory. To date, little research has
been published on the optimal way to implement HPV testing
within a screening programme.
The purpose of this study was to compare the costs and
logistical implications of implementing HPV triage in a routine
cervical screening programme (CSP) using data from the NHSCSP
‘Sentinel Sites’ study. A full description of this study and the
epidemiological findings has been published previously (Kelly
et al, 2011). Briefly six ‘sentinel sites’ were established to follow an
agreed protocol for the use of HPV testing for women with
borderline or mild dyskaryosis cytology results. At one site in
Bristol HPV testing was conducted within the cytology laboratory.
At Manchester HPV testing was conducted off-site at a micro-
biology laboratory. Four more sites: Liverpool, Manchester,
Northwick Park and Sheffield were spoke sites sending the
relevant cytology samples for HPV testing at the other two sites.
Together these six sites represent B10% of the English Screening
Programme. All women aged 25–64 with routine cytology reported
as borderline or mild dyskaryosis were eligible for inclusion in the
study. Women who tested negative for HPV were returned to
routine recall at 3 or 5 years depending on their age, and no further
information was collected; women who tested positive were
referred for a colposcopic examination. This study reports on
the detailed resource and costing data on implementation and
running costs that were collected alongside the project.
MATERIALS AND METHODS
For the purpose of costing two alternative service delivery models
for HPV testing were evaluated: a ‘hub and spoke model’, and an
‘integrated HPV/cytology laboratory’ (Figure 1). In the ‘hub and
spoke model’, cytology laboratories without HPV testing facilities
onsite, were considered as spokes. In line with the protocol,
cytology samples that indicated mild or borderline results required
HPV testing. With the hub and spoke model the relevant cytology
samples were transported to a central microbiology laboratory
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(the hub) for HPV testing. In contrast, with the integrated HPV
laboratory both cytology and HPV testing facilities are provided at
the same centre. Costs were estimated for both of the delivery
models. We present separately the costs of implementation and the
running costs.
The cost analysis was carried out from the NHS perspective. All
costs refer to 2009; where required costs were adjusted using the
Hospital and Community Health Service pay and price index
(Curtis 2010). Equipment and consumable costs associated with
HPV testing were estimated from the cost incurred at laboratories
and in consultation with suppliers based on 5 year contract for
leasing. Unit costs of staff time were derived from observational
studies, mostly undertaken specifically for the ‘Sentinel Sites’
study, and from existing tariffs and contracts, as well as from
published sources. Salary costs were then attributed for each
activity based on the mid-scale point for the corresponding band
in the Agenda for Change salary structure (Pay Circular (A for C)
1/2006, 2006, (see Appendix Tables A1 and A2). Salary costs
included qualifications and NHS employers’ costs (i.e, the
employer’s national insurance contribution plus 14% of salary
for employer’s contribution to superannuation).
Three separate categories of cost were considered: (a) training
and implementation costs (b) cost of administration, identifying
samples/specimen reception and transport (c) the cost of HPV
testing.
Training and implementation
A cost questionnaire was devised to assess the potential additional
costs of HPV testing for the ‘Sentinel Site’ laboratories not
performing HPV testing, the spoke laboratories. The questionnaire
assessed the following components of cost: training costs for
cytology laboratory staff, training cost for staff taking cytology
samples, cost of transporting liquid-based cytology samples for
HPV testing and administrative and other costs such as Informa-
tion Technology (IT) system change.
A cost questionnaire was also devised to identify the cost
incurred at HPV testing laboratories, which included staff training
costs, equipment and consumable costs. The questionnaire
identified the costs of training current staff for performing HPV
testing. As these training and implementation costs are a one-off
cost they are not included in subsequent cost analysis.
Cost of administration, identifying samples/specimen
reception and transport
In the ‘hub and spoke’ model, costs of administration and
identifying/specimen reception are incurred in both spoke
laboratories (i.e., cytology laboratories) and the hub laboratory
(HPV laboratory). Record sheets were developed to record the
amount of staff activity related to HPV testing in spoke
laboratories. Timings were recorded for the following activities:
identifying cytological samples for HPV testing, packing samples
for transporting to the HPV laboratory, updating clinical records
and administration time. Confidence intervals were estimated for
the timings assuming a normal distribution. Timings were
multiplied by cost weights for the type of staff performing each
activity as shown in the Appendix.
The slides were then transported to HPV laboratories. The costs
of spoke-to-hub transport of vials for processing were estimated
from the average journey transport costs and numbers of samples
transported. Record sheets were developed to record the amount of
staff activity related to HPV testing in a hub laboratory. The costs
of following staff activities were identified: specimen reception and
unpacking, updating clinical records and administration time.
In the integrated ‘HPV/cytology’ laboratory scenario there is no
requirement for transportation costs and the following costs were
included identifying cytological samples for HPV testing, updating
clinical records and administration time. Data from the record
sheet survey were used to determine the duration of time required
and grades of staff undertaking each activity and costed as
described above.
Costs of performing HPV tests
The cost of HPV testing includes equipment, consumables and
staff costs. Equipment and consumables for HPV testing were
based on the Qiagen HC2 (Crawley, England, UK) as used in the
‘Sentinel Sites’ study. A range of further HPV test alternatives are
currently on the market and further ongoing evaluation is being
undertaken on these tests. Potential differences could include
differences in price and batch sizes required to achieve efficiency
and avoid waste.
Costs were based on a manual preparation system as used in
‘Sentinel site’ laboratories undertaking the HPV testing. Again further
equipment is available from other manufacturers with elements of
automation, but this was not assessed within this evaluation. Costing
of HPV equipment/consumables was based on 5 year contract lease
prices and the modelled throughput of different sized HPV
laboratories. Indicative prices for equipment and maintenance were
obtained in confidence from the manufacturer. To maintain
confidentiality over indicative prices, we present prices in combina-
tion with the staff costs associated with preparing HPV tests.
A questionnaire was devised and sent to the laboratories
undertaking HPV testing to assess the costs of other equipment
not provided by the manufacturer and to identify the consumable
and staff time involved. Information was also obtained on the costs
of HPV consumables and staff processing time depending on the
number of tests being processed in each batch. Costs of HPV testing
are highly dependent on the batch size being processed at one time,
and costs are therefore presented for batches of different sizes.
During the ‘Sentinel Sites’ study, HPV tests were processed on a
twice weekly basis. An important consideration for HPV testing is
that it can be integrated within the overall cytology pathway to
meet government targets of women receiving their results within
14 days of a smear being taken (Department of Health, 2007).
Within the ‘Sentinel Sites’ study – some cytology laboratories
successfully managed to achieve a 14-day-turn-around time
including sending smears for HPV testing.
An alternative option would be that HPV processing was
conducted on a daily basis to further improve turn-around times;
however, this would only be economically efficient if there were a
sufficient quantity of tests. We assessed the volume of HPV tests
for each of these roll-out options by combining the data collected
for the epidemiological evaluation on the volume of HPV tests (for
both HPV triage of mild and borderlines and HPV test of cure)
Integrated
cytology/HPV
model
Cytology Cytology
Cytology
Cytology
HPV HPV
Hub and spoke 
delivery 
model
Cytology
Figure 1 Alternative delivery models.
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with estimates of the numbers of routine cytology tests from the;
the national screening programmes statistical returns (KC-61).
RESULTS
Training and implementation
A range of staff were involved with training for handling HPV tests
that would then be sent for processing at a hub HPV testing
laboratory. Training topics covered for identifying samples
included following protocols and correct placement of slide
numbers. Staff involved with packing cytology samples were given
training on: explaining protocols, quality control steps to ensure
correct totals were included and health and safety guidance.
Training on updating records with HPV results included verbal
explanation of protocols, instruction in the use of databases and
quality control steps to reduce transposition errors. Overall
training times for cytology staff varied from about an hour to
half a day, and were mainly provided in-house. It is likely that
these training costs for cytology staff would be similar for either
type of delivery model.
The number of staff who received training about HPV testing
provided by the cytology laboratories varied across the sites, from
52 to 212. Where fewer staff were trained, strategies were used such
as cascading information to staff and distributing HPV informa-
tion packs. An alternative model was to organise two formal
presentations for all cervical sample takers lasting 3 h, and then to
visit each general practitioner practice where there had been no
representation at either event. The cost of this training varied
between no direct costs (apart from staff time) to d2500. It is
anticipated that these training costs should be covered locally as
part of routine training updates for sample takers.
In the laboratory where HPV testing was already being
undertaken, training of staff on HPV testing was carried out
through in-house training. In the integrated HPV/cytology
laboratory, training was carried out by both the manufacturer
and in-house staff. The manufacturer provided training on
running assays and occasional troubleshooting matters. In-house
training was also provided for staff on receiving and preparing
samples, and reporting results.
There were some IT system changes in all the cytology
laboratories for changing codes, setting up the system and
establishing electronic links for the Exeter system. Each site had
to ensure that new result codes matched with the final result letters
sent to women. On average it took 3 days to perform IT changes.
Most sites did not incur any financial costs (beyond in house staff
time), other than one site that spent d2250 on IT system changes.
Staff time for administration, identifying samples/
specimen reception
Table 1 presents the time incurred for staff activity. Data were
collected at four out of the five sites where HPV testing was
conducted offsite (spokes). Timings were recorded for the
following activities: identifying cytological samples for HPV
testing, packing samples for transporting to the HPV laboratory,
updating clinical records and administration time. These data
show very similar results across three of the four sites, with the
total staff time per HPV sample at between 5 and 6min (Table 1),
at one site (Site C) the timings were significantly higher.
In the integrated cytology and HPV testing laboratory, only the
times for identifying samples for HPV testing and administration
for reporting the results were recorded (Table 2). At the hub HPV
processing centre hub (Manchester), we considered the costs of
specimen reception and administration including reporting results
back to the cytology laboratory (Table 3). Our data indicated that
the administration times were slightly lower at the hub HPV
testing centre, just under 2min compared with 4.5min at the
‘integrated HPV/cytology laboratory’ where the relevant samples
for HPV testing had to be identified. However, as specimens had to
be identified in the hub and spoke delivery model as shown in
Table 1, overall the combined staff time involved was much greater
for the ‘hub and spoke’ delivery model compared with the
integrated model.
Cost comparison between ‘hub and spoke model’ and
‘integrated cytology/HPV laboratory’: administration,
identifying samples/specimen reception and transport
Costs of the hub and spoke model were more expensive in part
because of transport costs. Each centre sent samples for HPV
testing to HPV laboratories twice a week. The average number of
samples sent per journey was 14 (range 10–18). The cost per
journey across centres varied from d5 to 50. Sentinel sites A and D
were located at relatively close proximities to HPV laboratories
Table 1 Time per HPV sample in cytology laboratories with HPV testing
offsite in seconds – mean (95% CI)
Activity A B C D
Identify sample 126 (50, 202) 45 (33, 57) 44 (28, 60) 70 (45, 96)
Packing 96 (56, 136) 58 (52, 64) 182 (130, 235) 67 (14, 119)
Update records 76 (39, 113) 91 (79, 103) 223 (181, 266) 175 (128, 220)
Admin time 28 (7, 49) 131 (117, 146) 338 (165, 511) 0 (0, 0)
Total 326 (153, 500) 325 (280, 370) 787 (502, 1071) 311 (187, 436)
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus. A–D repre-
sent timings at different laboratories – n¼ 6 batches at each site.
Table 2 Time per sample in HPV laboratories in seconds—mean
(95% CI)
Activity
Hub HPV
testing centre
Integrated cytology/
HPV laboratory
Specimen reception (separate)
Identifying samples (integrated)
62 (56, 68) 197 (123, 271)
Reporting results administration 50 (26, 76) 58 (28, 77)
Total 112 (62, 143) 254 (161, 349)
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus.
Table 3 Cost per sample—mean (95% CI) (range)
Activity
Hub HPV
testing centre
(d)
Integrated HPV/
cytology laboratory
(d)
Cost of staff time in cytology
laboratory (excluding laboratory
C)
2.66 (1.72, 3.61;
2.28 (1.56, 2.99))
NA
Transport cost NA
Transport distance—(150–
300 km),
2.76 (2.20, 3.33)
Transport distance–(o50 km) 0.44 (0.38, 0.50)
Specimen reception (separate) 0.24 (0.22, 0.26) —
Identifying samples (integrated) — 0.76 (0.48,1.05)
Reporting results 0.24 (0.12, 0.36) 0.28 (0.18, 0.37)
Total
Transport distance—(150–
300 km)
5.90 (5.20, 7.56)
Transport distance—(o50 km) 3.58 (3.38, 4.73) 1.04 (0.66, 1.42)
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus; NA¼ not
applicable.
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(just under 50 km) compared with sites B and C (150–300 km).
Sites A and D both incurred similar delivery costs – transporting
up to 12 samples at a price of d5 per box and a larger box cost d25
to transport up to 40 samples. Sites B and C generally sent samples
in a larger box that could contain 40 or more HPV samples at a
cost of between d40 and 50 per box. The average transport costs
per sample across the two sites located B50 km away were d0.44
(range d0.38 to 0.50). For those sites located further from the HPV
processing laboratory (150–300 km), average transport costs per
sample were higher at d2.76 (range d2.20–3.33; see Appendix Table
A3).
The ‘integrated HPV/Cytology’ laboratory leads to lower total
staff costs for administration, identifying samples/specimen
reception than that of ‘hub-and-spoke’ model. The total staff
administrative costs for the integrated laboratory were d1.04
compared with d3.14 for the integrated model. We also calculated
the total staff cost excluding laboratory C where the timings were
much higher than the other spoke laboratories and this lowered
the total cost to d2.76.
Overall, with the ‘hub-and-spoke’ model staff and transportation
costs ranged from d3.58 to 5.90 per sample depending on the
transportation distance, the equivalent costs for the integrated
laboratory were d1.04 (See Table 3). The integrated laboratory
does not incur any cost for transporting samples.
Costs of performing HPV testing
During the Sentinel sites project the Qiagen HC2 test was used.
Each kit has 96 wells including 8 wells that are used as controls for
each batch. There are economies of scale related to running full
batches including: the need for eight controls even with smaller
batches, use of slightly more consumable costs per test, higher
average equipment costs and increases in staff time per test. The
cost of HPV test varied from d12.83 to 20.97 depending on the
batch size. The cost of an HPV test includes the cost of equipment,
consumables, maintenance and staff time. These costs all increase
when running smaller batches. It is most cost-efficient to perform
HPV testing at full batch capacity (88 samples per batch) d12.83
per test. However, the marginal increase in cost for running 66
samples compared with 88 is only an additional d1.20 per test,
which if HPV testing was operating in a greater number of
laboratories that do not have sufficient capacity to run full batches
could potentially be offset by decreased transport costs.
The volume of tests for HPV processing centres serving different
sized cytology laboratories were estimated from the ‘Sentinel Site’
study data. Options included as follows:
 HPV testing in individual cytology laboratories (35 000 cytology
slides per year).
 HPV testing across cytology laboratories (100 000 cytology slides
per year).
 Two HPV laboratories at Strategic Health Authority (SHA) level.
 One HPV laboratory at SHA level.
 One National HPV processing laboratory.
Table 4 shows that running HPV testing daily in most of the
options would be inefficient as there would be unused capacity.
Running daily HPV testing with full batches would only be
possible if an HPV processing centre serves cytology laboratories
reading over 0.3 million slides per year.
On the basis of running HPV tests twice a week it is possible to
run full batches with two HPV testing centres per SHA. This may
also be a cost-efficient option if transport costs are reduced,
especially where the SHA covers a large geographical area.
However, it should be noted that the HPV testing workload figures
will vary from according to the protocols being followed.
DISCUSSION
Although there have been a number of cost-effectiveness analyses
conducted assessing the overall cost-effectiveness of implementing
HPV triage (Kim et al, 2002; Sherlaw-Johnson and Philipps, 2004;
Legood et al, 2006), we did not identify any previous detailed
costing analyses of the cost-efficiency of alternative roll-out
options. We found that the main implementation cost component
for the cytology laboratories was making changes to the IT system,
although no costs were substantive. Comparison of alternative
delivery models indicated that by setting up HPV processing
within the existing cytology laboratory, in an ‘integrated cytology/
HPV laboratory’ generated savings in staff time ranging from
between d2.54 and 4.86. The additional costs incurred by having a
‘hub and spoke model’ with cytology laboratories sending samples
to another site for processing included the cost of transportation
and extra administrative workload.
Our estimate for the cost of HPV testing including the staff,
consumable and equipment cost ranged from d12.83 to 20.97
depending on the batch size. To maintain confidentiality over
prices we did not present disaggregated costs. However, our result
for running full batches d12.83 is only slightly higher than an
estimate from the ARTISTIC study for full batches of d10.57–10.38
(Kitchener et al, 2009).
When considering alternative implementation options a key
issue is the cost of HPV testing that increase when running smaller
batches if the Hybrid Capture II system is used. Overall, our results
indicate that with two testing centres per SHA it would be possible
to have full batch sizes, given a twice weekly testing schedule
and this would be consistent with government targets for a
Table 4 Volume of HPV tests for alternative roll-out options (CI) and costs (range)
Number of HPV
testing centres
required
Annual
cytology
workload
Annual HPV testing
workload
Tests per batch
if testing twice a
week
Cost per test if
testing twice a
week (d)
Tests per
batch if testing
everyday
Cost per test if
testing
everyday (d)
Each cytology
laboratory
103 35 000 2514 (2447, 2538) 24 (24, 25) 20.31 (20.31,20.01) 10 (9, 10) 30.62 (32.58,
30.62)
Sharing across
several
laboratories
36 100 000 7183 (6990, 7380) 69 (67, 71) 14.70 (14.77, 13.80) 28 (27, 28) 19.25 (19.49,
19.25)
Two HPV testing
laboratories per
SHA
20 180 000 12 390 (12 582, 13 284) 124 (121, 128) 12.83a 50 (48, 51) 15.95 (16.09,
15.88)
One HPV testing
centre per SHA
10 360 000 25 859 (25 164, 26 568) 249 (242, 255) 12.83a 99 (97, 102) 12.83a
One National
laboratory
1 36 00 000 25 8291 (251 640, 265 680) 2486 (2420, 2555) 12.83a 995 (968, 1021) 12.83a
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus; SHA¼ Strategic Health Authority. aAssumes all batches run at maximum capacity 88 samples per batch.
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14-day-turn-around (Department of Health, 2007). Keeping within
the 14-day-turn-around time is important for ensuring there is not
disutility for women waiting for results. Given that the cost per
HPV test with this batch size is only an extra d1.20, this may also
be a cost-efficient option if transport costs are reduced, especially
where the SHA covers a large geographical area. Although Hybrid
Capture II was used within this evaluation, alternative options that
require smaller batch sizes are also available and these have not
been evaluated within this study.
A limitation of our analysis is that we have not evaluated the
cost of building space and utilities so in practice the total costs
may be higher. Our estimates of the volumes of HPV samples to be
processed are based on mean HPV positivity rates for mild and
borderline cytology results. In practice as shown in the Sentinel
Site study, (Kelly et al, 2011) there will be some variations locally
depending with some place having higher HPV positivity rates and
therefore higher-throughput volumes and others having lower
rates and throughput volumes.
An alternative approach would be to have one national
laboratory or only a few very large laboratories. A further
advantage of processing HPV tests at higher volumes is the
potential to generate savings from economies of scale. For
example, further HPV equipment could be used that increases
the automation of the HPV testing process. The results of this
project suggest that transport costs were significantly higher over
longer distances, although it is possible that lower and more
efficient transport options could be found such as transferring
samples to a central point before sending on. Primary HPV testing,
which is likely to be on the future policy agenda, would generate
many more samples and thus make it possible to achieve
economies of scale within a smaller screened area.
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APPENDIX
Table A1 Cost per minute for laboratory staff
Staff Cost per min (d) Source
MLA 0.19 Curtis 2010; Pay Circular
(A for C) 1/2006
MLA3 0.20 Curtis 2010; Pay Circular
(A for C) 1/2006
Cytoscreener 0.24 Curtis 2010; Pay Circular
(A for C) 1/2006
BMS 0.29 Curtis 2010; Pay Circular
(A for C) 1/2006
Senior BMS 0.42 Curtis 2010; Pay Circular
(A for C) 1/2006
Table A1 (Continued )
Staff Cost per min (d) Source
Pathologist 1.36 Kitchener et al, 2009
Advanced practitioner 1.10 Curtis 2010; Pay Circular
(A for C) 1/2006
Consultant 2.82 Curtis 2010; Pay Circular
(A for C) 1/2006
Abbreviations: BMS¼ biomedical scientist; MLA¼Medical Laboratory Assistant.
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Table A2 Activities undertaken by staff type
Cyto screener
(%)
BMS
(%)
Senior BMS
(%)
MLA
(%)
MLA3
(%)
Identify
sample
— 33 50 17 —
Packing 24 48 28 — —
Update
records
— 46 27 — 27
Admin time 8 68 24 — —
Total costs of staff activities were calculated by multiplying the staff time involved by a
weighted cost based on different staff undertaking each activities. Confidence
intervals for staff costs were generated by using these upper and lower confidence
intervals for staff time.
Table A3 Transport cost
Site A B C D
How many times a week
are LBC samples sent to
HPV test centre?
2 2 2 2
Cost per journey d5 for 10–16
samples d25
for 40þ
samples
d40þ packaging d50 d5 for 12
samples in
a box
On average how many
samples are sent each
journey
10 18 15 13
Distance from HPV testing
laboratory in km
49 293 158 47
What is the maximum
number of samples that
can be sent at a time for
the same price?
B200 for d25 NA Up to
1 kg in
weight
12
centrifuge
tubes max
per box
Average transport cost d0.50 d2.20 d3.33 d0.38
Abbreviations: HPV¼ human papillomavirus; LBC¼ liquid-based cytology.
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